EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Focal Adhesion Kinase Intersects With the BRD4‐MYC Axis and YAP1 to Drive Tumor Cell Growth, Phenotypic Plasticity, Stemness, and Metastatic Potential in Colorectal Cancer

Rongbo Han, Junfeng Shi, Kai Cheng, Zian Wang, Yecang Chen, Orion Spellecy, Abu Saleh Mosa Faisal, Isha Aryal, Jinfei Chen iD, Rolf Craven, Olivier Thibault, Lauren Baldwin und 9 weitere

Cancer Medicine · 2025

DOI: 10.1002/cam4.71227 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Rongbo Han und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Nutritional Sciences, College of Medicine, University of Kentucky, Lexington, Kentucky, USA. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Transcription Factors, Proto-Oncogene Proteins c-myc, Neoplastic Stem Cells. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: American Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Colorectal cancer (CRC) remains one of the leading causes of cancer‐related death worldwide due to the lack of effective therapies. Here we explored the clinical basis and therapeutic promise of the integrin‐focal adhesion kinase (FAK)‐dependent pathway for CRC. Methods and Results Our bioinformatic and histological analyses showed that FAK was markedly upregulated at both mRNA and protein and signaling levels in the two CRC patient cohorts. Particularly, the portion of carcinomas carrying active FAK (Y 397 phosphorylation) increased by threefold from stage I to III/IV tumors or metastatic lesions. Consistent with this clinic landscape, FAK inhibition via knockdown or chemical inhibitors suppressed tumor cell growth largely in the subset of CRC cell lines with low MYC expression. In contrast, the FAK inhibition was less effective in the cell line pool with high MYC expression. The resistance to FAK targeting diminished upon a co‐inhibition of BRD4 via BET inhibitors. It coincided with an induction of cell cycle arrest at G1‐S and G2‐M phases, elevated apoptosis and chemosensitivity (paclitaxel and oxaliplatin), and impaired stemness. Mechanistically, the BET inhibitor induced an EMT‐like phenotype, tilting tumor cell dependence toward the integrin‐FAK axis. Moreover, inhibiting FAK alone or in combination with SRC or BRD4 markedly suppressed cell motility and the YAP or MYC activation, and restored the expression of the long isoform BRD4. Also, co‐genomic/genetic dysregulations of FAK and YAP1 or SRC strongly correlated with poor disease‐free patient survival.

Conclusion

Overall, our study highlights the potent pro‐malignant role of the integrin‐FAK axis in CRC, fueling its targeting as a single agent or synthetic lethal‐based therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsTranscription FactorsProto-Oncogene Proteins c-mycNeoplastic Stem CellsCell Cycle ProteinsAdaptor Proteins, Signal TransducingFocal Adhesion Kinase 1Focal Adhesion Protein-Tyrosine KinasesHumansYAP-Signaling ProteinsCell ProliferationCell Line, TumorSignal TransductionGene Expression Regulation, NeoplasticCell MovementNeoplasm MetastasisPhenotypeBromodomain Containing Proteins

Stichwörter der Autor:innen

BRD4FAKMYCcolorectal cancermetastasistumor growth

Substanzen

YAP-Signaling ProteinsYAP1 protein, humanTranscription FactorsProto-Oncogene Proteins c-mycCell Cycle ProteinsBRD4 protein, humanAdaptor Proteins, Signal TransducingPTK2 protein, humanFocal Adhesion Kinase 1MYC protein, human

Autor:innen und Institutionen

  • Department of Pharmacology and Nutritional Sciences, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.
  • Department of Oncology, The Fourth Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, China.
  • Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, China.
  • Department of Pathology, Nanjing Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu Province, China.
  • College of Food Science and Technology, Shanghai Ocean University, Shanghai, China.
  • Markey Cancer Center and Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.

ORCID-Profile: Jinfei Chen, Frederick Ueland, Xiuwei Yang

Förderung

  • American Cancer Society

Zitieren

APA

Han, R., Shi, J., Cheng, K., Wang, Z., Chen, Y., Spellecy, O., Faisal, A. S. M., Aryal, I., Chen, J., Craven, R., Thibault, O., Baldwin, L., Brewer, L. D., Erfani, S., Wang, C., Guo, Z., Chen, E., Yang, B., Ueland, F., …, & Yang, X. (2025). Focal Adhesion Kinase Intersects With the BRD4‐MYC Axis and YAP1 to Drive Tumor Cell Growth, Phenotypic Plasticity, Stemness, and Metastatic Potential in Colorectal Cancer. Cancer Medicine. https://doi.org/10.1002/cam4.71227

Vancouver

Han R, Shi J, Cheng K, Wang Z, Chen Y, Spellecy O, et al. Focal Adhesion Kinase Intersects With the BRD4‐MYC Axis and YAP1 to Drive Tumor Cell Growth, Phenotypic Plasticity, Stemness, and Metastatic Potential in Colorectal Cancer. Cancer Medicine. 2025. doi:10.1002/cam4.71227

BibTeX
@article{Han2025,
  author = {Han, Rongbo and Shi, Junfeng and Cheng, Kai and Wang, Zian and Chen, Yecang and Spellecy, Orion and Faisal, Abu Saleh Mosa and Aryal, Isha and Chen, Jinfei and Craven, Rolf and Thibault, Olivier and Baldwin, Lauren and Brewer, Lawrence D and Erfani, Sonia and Wang, Chi and Guo, Zhenheng and Chen, Eric and Yang, Burton and Ueland, Frederick and Guo, Ruihua and Yang, Xiuwei},
  title = {Focal Adhesion Kinase Intersects With the BRD4‐MYC Axis and YAP1 to Drive Tumor Cell Growth, Phenotypic Plasticity, Stemness, and Metastatic Potential in Colorectal Cancer},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71227}
}
Kostenlos starten →